ifpma.org

On 6 July 2026, IFPMA published a statement ahead of the seventh meeting of the Intergovernmental Working Group (IGWG 7) on the WHO Pandemic Agreement. The extension of the negotiations provides an important opportunity to get the PABS right, and recent outbreaks such as Ebola and Hantavirus clearly highlight the practical challenges that these discussions must address.

Report #AlwaysInnovating: Pharmaceutical Industry Facts & Figures This compendium of facts and figures aims to provide a snapshot of the contribution of the pharmaceutical industry. Pharmaceutical companies are at the forefront of developing medicines and vaccines that change how we fight and prevent disease and help solve today’s biggest health challenges. In addition to their contribution to healthier societies, pharmaceutical companies also...

The World Intellectual Property Organization (WIPO), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and Interpat have launched a new partnership that underlines a shared commitment to intellectual property supporting health innovation.

On 30 June, in response to reforms introudced in Germany, BCR Secretary General, and IFPMA Director General, Dr. David Reddy, said: “The legislation introduced by the German government undermines the value of medical innovation, global competitiveness and patient access to new medicines.

Data-driven R&D is important for patients, populations, and health systems Every patient’s experience – getting a diagnosis, starting treatment, living with side effects, seeing what works and what does not – generates information that can help improve their care and care for others.

R&D is the engine transforming health outcomes for people, economies, and societies. Investment in the research and development (R&D) of innovative medicines and vaccines has driven unprecedented progress in health, economic growth, and social well-being. New breakthrough therapies offer hope to millions of people worldwide. Between 2004-2023, 942 novel active substances launched globally.

On 22 June 2026, IFPMA delivered a statement at the UN High-Level Meeting on HIV/AIDS in New York. Excellencies, distinguished delegates, I am pleased to speak on behalf of the IFPMA, representing the innovative pharmaceutical industry. As Member States gather at this High-Level Meeting to renew global commitments on HIV/AIDS, IFPMA welcomes the Political Declaration’s continued ambition to end AIDS as a public health threat by 2030.

Routine immunisation for adults and children alike is more than a health service — it’s core to our health security. Getting this right can determine how fast and effectively countries can respond in a crisis. Later this year, the UN will hold a High-Level Meeting on Pandemic Prevention, Preparedness and Response. This will be a key moment to renew political commitment to health security and identify practical actions to reduce the impact of future outbreaks and pandemics.

The global innovative pharmaceutical industry welcomes the G7 leaders’ commitment to strengthening international cooperation and advancing a balanced and durable growth agenda. IFPMA supports the direction G7 leaders have set and reiterates that a strong life sciences sector is critical to support these shared objectives.

The global pharmaceutical industry underlines the commitment of the sector to support the response to the latest Ebolavirus outbreak, and calls for the latest outbreak to be a “wake up call” for negotiators discussing the details of the Pandemic Agreement.